Cargando…
Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500836/ https://www.ncbi.nlm.nih.gov/pubmed/34614513 http://dx.doi.org/10.1182/bloodadvances.2021005998 |
| _version_ | 1784580528803938304 |
|---|---|
| author | Herishanu, Yair Avivi, Irit Levi, Shai Shefer, Gabi Bronstein, Yotam Moshiashvili, Miguel Morales Ziv, Tomer Scarfò, Lydia Perry, Chava Ghia, Paolo |
| author_facet | Herishanu, Yair Avivi, Irit Levi, Shai Shefer, Gabi Bronstein, Yotam Moshiashvili, Miguel Morales Ziv, Tomer Scarfò, Lydia Perry, Chava Ghia, Paolo |
| author_sort | Herishanu, Yair |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8500836 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85008362021-10-12 Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia Herishanu, Yair Avivi, Irit Levi, Shai Shefer, Gabi Bronstein, Yotam Moshiashvili, Miguel Morales Ziv, Tomer Scarfò, Lydia Perry, Chava Ghia, Paolo Blood Adv Research Letter American Society of Hematology 2022-01-07 /pmc/articles/PMC8500836/ /pubmed/34614513 http://dx.doi.org/10.1182/bloodadvances.2021005998 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
| spellingShingle | Research Letter Herishanu, Yair Avivi, Irit Levi, Shai Shefer, Gabi Bronstein, Yotam Moshiashvili, Miguel Morales Ziv, Tomer Scarfò, Lydia Perry, Chava Ghia, Paolo Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia |
| title | Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia |
| title_full | Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia |
| title_fullStr | Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia |
| title_full_unstemmed | Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia |
| title_short | Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia |
| title_sort | six-month antibody persistence after bnt162b2 mrna covid-19 vaccination in patients with chronic lymphocytic leukemia |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500836/ https://www.ncbi.nlm.nih.gov/pubmed/34614513 http://dx.doi.org/10.1182/bloodadvances.2021005998 |
| work_keys_str_mv | AT herishanuyair sixmonthantibodypersistenceafterbnt162b2mrnacovid19vaccinationinpatientswithchroniclymphocyticleukemia AT aviviirit sixmonthantibodypersistenceafterbnt162b2mrnacovid19vaccinationinpatientswithchroniclymphocyticleukemia AT levishai sixmonthantibodypersistenceafterbnt162b2mrnacovid19vaccinationinpatientswithchroniclymphocyticleukemia AT shefergabi sixmonthantibodypersistenceafterbnt162b2mrnacovid19vaccinationinpatientswithchroniclymphocyticleukemia AT bronsteinyotam sixmonthantibodypersistenceafterbnt162b2mrnacovid19vaccinationinpatientswithchroniclymphocyticleukemia AT moshiashvilimiguelmorales sixmonthantibodypersistenceafterbnt162b2mrnacovid19vaccinationinpatientswithchroniclymphocyticleukemia AT zivtomer sixmonthantibodypersistenceafterbnt162b2mrnacovid19vaccinationinpatientswithchroniclymphocyticleukemia AT scarfolydia sixmonthantibodypersistenceafterbnt162b2mrnacovid19vaccinationinpatientswithchroniclymphocyticleukemia AT perrychava sixmonthantibodypersistenceafterbnt162b2mrnacovid19vaccinationinpatientswithchroniclymphocyticleukemia AT ghiapaolo sixmonthantibodypersistenceafterbnt162b2mrnacovid19vaccinationinpatientswithchroniclymphocyticleukemia |